Pyoderma gangrenosum – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pyoderma gangrenosum – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy https://clinicaltrials.eu/trial/study-on-spesolimab-for-adults-with-pyoderma-gangrenosum-requiring-systemic-therapy/ Wed, 29 Apr 2026 15:02:35 +0000 https://clinicaltrials.eu/trial/study-on-spesolimab-for-adults-with-pyoderma-gangrenosum-requiring-systemic-therapy/ This clinical trial is focused on a skin condition called pyoderma gangrenosum, which is characterized by painful ulcers. The study is testing a treatment called spesolimab, also known by its code name BI 655130. Spesolimab is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein. The trial will compare the effects of spesolimab to a placebo, which is a substance with no active medication, to see if spesolimab is more effective in treating this condition.

The purpose of the study is to determine if spesolimab can help achieve complete healing of the ulcers caused by pyoderma gangrenosum. Participants in the study will receive either spesolimab or a placebo and will be monitored over a period of time to see if their ulcers heal completely. The study will last up to 52 weeks, with the main focus on the first 26 weeks to see if the ulcers close completely and remain healed for at least two weeks.

Throughout the study, participants will have regular check-ups to monitor their progress. The study aims to provide valuable information on whether spesolimab can be a safe and effective treatment option for people suffering from pyoderma gangrenosum. The ultimate goal is to find a treatment that can help reduce the area of the ulcers and improve the quality of life for those affected by this condition.

]]> Study on Vilobelimab and Drug Combination for Treating Ulcerative Pyoderma Gangrenosum in Adults https://clinicaltrials.eu/trial/study-on-vilobelimab-and-drug-combination-for-treating-ulcerative-pyoderma-gangrenosum-in-adults/ Wed, 29 Apr 2026 14:25:51 +0000 https://clinicaltrials.eu/trial/study-on-vilobelimab-and-drug-combination-for-treating-ulcerative-pyoderma-gangrenosum-in-adults/ This clinical trial is focused on studying the treatment of ulcerative pyoderma gangrenosum, a rare skin condition that causes painful ulcers. The study will evaluate the effectiveness and safety of a medication called vilobelimab, which is administered as a solution for infusion. Participants in the trial will receive either vilobelimab or a placebo, which is a substance with no active medication, to compare the outcomes.

The purpose of the study is to determine how well vilobelimab works in treating ulcerative pyoderma gangrenosum. The trial will involve multiple visits over a period of time, where participants will receive the treatment and be monitored for any changes in their condition. The study will assess the healing of the ulcers, any reduction in pain, and overall improvement in the skin condition.

In addition to vilobelimab, the study will also involve the use of other medications such as betamethasone, methylprednisolone, prednisone, cortisone acetate, dexamethasone, hydrocortisone, prednisolone, triamcinolone, and fludrocortisone. These medications are glucocorticoids or corticosteroids, which are commonly used to reduce inflammation and suppress the immune system. The trial will help to understand the potential benefits and safety of vilobelimab in comparison to these other treatments.

]]>